Introduction
Peroxisome proliferators constitute a novel class of non-mutagenic hepatocarcinogens, all of which induce a similar pleiotropic response consisting of hepatomegaly, proliferation of peroxisomes in the liver parenchyma] cells and the induction of several hepatic enzymes, particularly those of the peroxisomal fatty acid /3-oxidation system (1) (2) (3) . Presently several structurally dissimilar hypolipidemic compounds, including the widely used drug clofibrate, and certain phthalate ester plasticizers are the two major categories of agents that are recognized as peroxisome proliferators (2) . The lack of mutagenicity of these agents led to the proposal that hepatocarcinogenesis is not related to the direct initiating effect of these chemicals (or their possible metabolites), but linked to metabolic disturbance(s) emanating from sustained increase in the number of peroxisomes in liver cells (4) . Elucidation of the mechanism of induction of peroxisome proliferation and associated enzymes by these agents is, therefore, considered essential in order to understand the role of peroxisomes in liver carcinogenesis induced by these xenobiotics which do not appear to interact with and damage DNA (5, 6) . This commentary is a brief review of the biological effects of peroxisome proliferators and of possible mechanisms of induction of pleiotropic responses leading to the development of hepatocellular carcinomas, focusing in particular on the hypothesis that these agents exert their effects by interacting with a specific receptor(s).
Peroxisomes: structure and functions
Peroxisomes are single membrane-limited cytoplasmic organelles which are present in a wide variety of cells in both animals and plants (7, 8) . In mammals, the morphological and biochemical properties of peroxisomes of liver and to some extent those of the kidney have been well characterized (9) . In liver parenchyma! cells, peroxisomes measure -0.2-1 /im in diameter and are very few in number, accounting for less than 2% of the hepatocyte cytoplasmic volume under physiological conditions. These organelles contain a finely granular or flocculent matrix of moderate electron density. Peroxisomes in liver cells of several species of animals are easily identifiable due to the presence, in these organelles, of crystalloid cores or nucleoids containing the enzyme urate oxidase (10, 11) . In some species, including the human, peroxisomes lack nucleoids, signifying the absence of this enzyme uricase (12) . Irrespective of the presence or absence of nucleoids, positive identification of peroxisomes is made relatively easily by recently developed cytochemical and immuno-*Abbreviations: CoA, coenzyme A; Wy-14643, [4-chloro-6-(2,3-xylidino)2-pyrimidinylthio]acetic acid; BR-931, 4-chloro-6(2,3-xylidino)2-pyrimidinylthio (N-B-hydroxyethyi)-acetamide; DEHP, di-(2-ethyllexyl)phthalate; DEHA, di-(2-ethylhexyl)adipate; GGT, 7-glutamyltranspeptidase. cytochemical techniques to localize one or more of the peroxisome specific enzymes (13 -15) .
During the embryonic development, peroxisomes appear in rat liver on day 14 or 15 of gestation and increase in number by gestational day 19 (16, 17) . The failure of demonstration of peroxisomes by sensitive cytochemical techniques before day 14 of gestation in rat embryos is intriguing in view of the postulation that peroxisomes are not formed de novo and are propagated from germ cells to the embryo (18) . The regulation of various peroxisomal enzymes during the fetal development remains to be established.
Since the initial observation of the association of urate oxidase with peroxisome fraction, a total of over 40 enzymes have been identified as belonging to these organelles (19, 20) . Catalase is the marker enzyme and is, therefore, a hallmark of peroxisomes derived from different sources (7) . In addition to catalase, these organelles must possess at least one I^C^-generating oxidase to fulfil the biochemical concept of peroxisome, which implies that these organelles are capable of producing and degrading hydrogen peroxide (2) . Hepatic peroxisomes of rat and possibly other mammals contain five oxidases which utilize oxygen and generate H 2 O 2 . The oxidases in rat liver include a-hydroxyacid oxidase, D-amino acid oxidase, polyamine oxidase, urate oxidase and fatty acyl-coenzyme A (CoA*) oxidase (7, 21) . In human liver and in the livers of certain other species, urate oxidase is not present due to deletion or inactivation of this gene. Of the variety of enzymes present in rat liver, catalase and the enzymes of the fatty acid jS-oxidation system have been well characterized and are of major importance in any consideration of xenobiotic-induced peroxisome proliferation in investigating the mechanisms of peroxisomal enzyme induction and in evaluating the relationship between peroxisome proliferation and hepatocarcinogenesis.
Peroxisomal enzymes are synthesized on free polysomes and are selectively transported to and segregated within the peroxisome (22, 23) . How these newly synthesized peroxisomal proteins, most of which lack a signal peptide (23) , are recognized by the peroxisome membrane and accumulate in these organelles is not fully understood. It is conceivable that these proteins have selective domains which are recognized by the receptor(s) that may be present on peroxisome membrane and are then internalized.
Based on the nature of the enzymes detected in these organelles, several functions have been attributed to peroxisomes. These include respiration, gluconeogenesis, thermogenesis, purine catabolism, fatty acid catabolism, and some role in glycerolipid and plasmalogen synthesis (2, 9, 20, 24, 25) .
Peroxisome proliferators
The remarkable biological phenomenon of the induction of peroxisome proliferation in parenchyma] cells of liver of rats fed a diet containing clofibrate, a hypolipidemic drug, was first described over 20 years ago (26) . Since then several structurally dissimilar hypolipidemic agents and a few commonly used industrial phthalate ester plasticizers have been shown to induce peroxisome proliferation in the hepatocytes of several species, including primates (2,27-31). The majority of compounds identified to date as peroxisome proliferators belong to the family of clofibrate-like hypolipidemic agents. Several of the structural analogs of clofibrate are extremely potent inducers of peroxisome proliferation and hepatocarcinogenesis in rats and mice (2, 32) . These include methyl clofenapate, ciprofibrate, nafenopin, gemfibrozil, bezafibrate and fenofibrate, which are several orders of magnitude more potent than the prototype compound, clofibrate, in inducing hypolipidemia, peroxisome proliferation and liver carcinogenesis (33) . In addition, several hypolipidemic compounds which are not structurally related to clofibrate are also identified as potent peroxisome proliferators (2) . Of this subclass, [4-chloro-6-(2,3-xylidino)2-pyrimidinylthio]acetic acid (Wy-14643), 4-chloro-6(2,3-xylidino)2-pyrimidinylthio(N-|8-hydroxyethyl)acetamide (BR-931) and tibric acid are more potent than clofibrate in inducing liver tumors in rats and mice (32, 34, 35) . The plasticizers di-(2-ethylhexyl)phthalate (DEHP) and di-(2-ethylhexyl)adipate (DEHA) were identified as peroxisome proliferators nearly 10 years ago (36) . The plasticizer DEHP is one of the more widely used plasticizing agents employed in the manufacture of polyvinyl chloride plastics (37) . DEHP comprises up to 50% by weight of some of the plastics which are in common use, and since it is not covalently linked to the plastic's matrix, it gradually leaches out into the external environment. Involuntary exposure to DEHP is a well-recognized occurrence in the general population and in individuals receiving transfusions of blood products, hemodialysis or other types of dialysis (38, 39) . In the USA the annual production of phthalate esters is approximately 4.5 x 10 8 kg (40) of which DEHP accounts for 1.7 X 10 8 kg (41). Thus, hypolipidemic drugs, which are increasingly used in the therapeutic control of hyperlipidemia (a major risk factor in the pathogenesis of coronary heart disease), and plasticizers, which are ubiquitous in the environment, may pose a potential risk to humans because of their ability to induce the characteristic pleiotropic response.
Tissue specificity of pleiotropic response
Peroxisome proliferators, as a group, produce a predictably similar pleiotropic response, which includes hepatomegaly, an increase in the number of peroxisomes in hepatic parenchymal cells, and an increase in the activity of several enzymes, especially those associated with peroxisome (2, 28, 42) . Since all peroxisome proliferators tested so far in long-term studies have been found to induce liver tumors, the hepatocarcinogenicity is considered to be a delayed component of the pleiotropic response resulting from the prolonged exposure to these xenobiotics.
Hepatomegaly and peroxisome proliferation
Liver enlargement occurs within a few days of dietary administration of peroxisome proliferator, reaches a steady-state level within 7 -10 days and is maintained as long as the xenobiotic is administered (2) . The degree of observed hepatomegalic effect depends to a large extent on the potency of the compound and on the dose administered (32, 43) . Accordingly, the quantities of the compound necessary to produce a measurable effect on liver size and peroxisome proliferation differ considerably and the increment of these parameters may range from 10 to 100% of the control. It is important to note that all peroxisome proliferators are not equally effective in increasing the number of peroxisomes and on equivalent weight basis some of the clofibrate analogs such as ciprofibrate are 1000 times more potent than acetylsalicylic acid and DEHP in inducing peroxisome proliferation (32, 44) . The liver enlargement is due both to hyperplasia and hypertrophy of hepatocytes (35, 45, 46) . The hyperplasia is evident as early as 24 h and reaches a maximum within 5-7 days, followed by a gradual decrease once the maximum hepatomegaly is reached. Mitotic activity in the liver of rats and mice chronically exposed to a peroxisome proliferator may remain slightly higher than the control (45) . Hypertrophy of liver cells is secondary to marked increases in the numerical and volume densities of peroxisomes (46, 47) . These organelles may account for up to 25% of hepatocyte cytoplasmic volume in the livers of rats and mice treated with potent peroxisome proliferators such as Wy-14643, methyl clofenapate and ciprofibrate (46, 47) .
Hepatic enzyme changes
The induction of maximal peroxisome proliferation in liver cells of rats and mice is accompanied by predictable, but variable, increases in the activities of several hepatic enzymes (2, 33) , including glycerol phosphate dehydrogenase, cytochrome c oxidase, carnitine acetyltransferase, carnitine octonoyltransferase, carnitine palmitoyltransferase, acyl-CoA:dihydroxyacetone phosphate acyltransferase, cytosolic epoxide hydrolase, aconitase, catalase, and the enzymes responsible for the /3-oxidation of fatty acids (2, 3, (48) (49) (50) (51) (52) (53) (54) . Of these, increases in the activities of the peroxisomal marker enzyme catalase and the three enzymes of the peroxisomal fatty acid /3-oxidation system are considered primary effects of these xenobiotic agents and relevant to the discussion of the role of peroxisomes in liver carcinogenesis (2, 51) . The increase in the activity and biosynthesis of catalase is ~ 2-fold, with maximum increase in the peroxisome population in hepatocytes, whereas the activity of peroxisomal j3-oxidation increases 20-to 30-fold (53) . Although the activity of the fatty acid /3-oxidation system and the quantity of peroxisome-proliferation-associated bifunctional enoyl-CoA hydratase/3-hydroxyacylCoA dehydrogenase (M r 80 000) generally change in parallel with increases in peroxisome volume density, the increase in catalase activity is not proportional. Irnrnunocytochemical studies utilizing protein A-gold labeling procedure have demonstrated that catalase is proportionately less in proliferated peroxisomes when compared with normal peroxisomes, whereas the converse is true for the /3-oxidation enzymes (55) . Recent evidence clearly indicates that the mRNA content of fatty acyl-CoA oxidase and the bifunctional enoyl-CoA hydratase/3-hydroxyacyl-CoA dehydrogenase, the first two enzymes of the /J-oxidation system are regulated at the transcriptional level in a coordinated fashion by the peroxisome proliferators (53) . The catalase mRNA increases about 1.4-fold, but the transcription rate of catalase gene does not appear to change (53) . This, coupled with the previous observation that peroxisome proliferation is inducible by these xenobiotics in the absence of catalase synthesis (56) , clearly indicates that the activation of catalase gene is not an essential component of the pleiotropic response. The regulation of other enzymes has not been as extensively investigated.
Hepatocarcinogenicity
The development of hepatocellular carcinomas in mice fed a diet containing a peroxisome proliferator was first reported in 1976 (57) . Since then, several hypolipidemic compounds and the plasticizers, DEHP and DEHA, have been shown to induce liver tumors in rats and mice (2, 32, 54, (58) (59) (60) (61) (62) (63) . The latency period and the incidence of tumors appear to correlate well with the effectiveness of the compound to induce peroxisome proliferation. With potent peroxisome proliferators (i.e. Wy-14643, ciprofibrate and methyl clofenapate), liver tumors develop in nearly 100% of rats within 50-60 weeks when administered at dietary levels ranging from 0.125 to 0.025% (w/w) (54, 60) . With less potent agents such as clofibrate and DEHP, liver tumors develop between 70 and 104 weeks at dietary levels ranging from 0.5 to 1.2% (w/w) (59,63). Rao et al. (64) have shown that in Wy-14643-induced hepatocarcinogenesis in rats, altered hepatocyte foci appear by 22 weeks and neoplastic liver nodules appear between 26 and 50 weeks with hepatocellular carcinomas emerging thereafter. The majority of the liver tumors induced by different peroxisome proliferators are well-differentiated hepatocellular carcinomas, with predominantly trabecular histological pattern. Metastases are encountered in -20-40% of rats and mice with peroxisome proliferator-induced hepatocellular carcinomas (65) .
Altered hepatic foci, nodules and hepatocellular carcinomas induced by peroxisome proliferators are indistinguishable histologically from those induced by other classes of hepatocarcinogens. Of considerable interest, however, is the observation that Y-glutamyltranspeptidase (GGT) and the placental form of glutathione-S-transferase, the two universally used phenotypic markers in the study of initiation and promotion of liver carcinogenesis, are usually negative in peroxisome proliferator-induced liver lesions (66) (67) (68) . The absence of GGT staining is not due to inactivation of enzyme by the xenobiotic since discontinuation of drug treatment for 8 weeks failed to induce GGT positivity in such putative preneoplastic and neoplastic liver lesions. Recent immunohistochemical studies have shown that the GGT protein is absent in these lesions, implying that it is not expressed (69) . The mRNA for GGT is also not detectable by blot analysis in the peroxisome proliferator-induced liver tumors, suggesting that these agents do not derepress the GGT gene during carcinogenesis (70) . On the basis of these observations, it has been suggested that derepression of GGT gene activity, although frequently seen in liver tumors induced by mutagenic chemicals, is not an essential step linked with either initiation or promotion of hepatocarcinogenesis (67, 68) .
The pleiotropic response outlined above is typically induced by structurally dissimilar peroxisome proliferators. The hypothesis that sustained induction of peroxisome proliferation and specific peroxisomal enzymes form the basis for carcinogenesis implies that tumors should develop only in organs which display peroxisome proliferation (42) . Available evidence suggests that peroxisome proliferator pleiotropic response in rats and mice is observed to a large extent in liver and to a limited degree in the proximal tubular epithelium of the kidney. Analysis of various tissues of rats treated with ciprofibrate, a potent peroxisome proliferator, revealed no appreciable increases in peroxisome number, peroxisomal /3-oxidation activity and the mRNA levels of the peroxisomal fatty acyl-CoA oxidase and enoyl-CoA hydratase in non-hepatic tissues, except for subtle increases in kidney (71) . The tissue specificity of this inductive response is also substantiated by the studies utilizing hepatocyte transplantation protocol. Hepatocytes transplanted in the subcutaneous fat or in the anterior chamber of the eye of rats responded to the peroxisome-proliferative effects of ciprofibrate, as well as the plasticizer DEHP (72, 73) . In addition, the transdifferentiated hepatocytes in rat and hamster pancreas have also been shown to respond remarkably well to the inductive effects of peroxisome proliferators (74, 75) . From these studies it is concluded that peroxisome proliferator pleiotropic response is largely confined to liver. The development of tumors almost exclusively in liver of rats and mice treated with these agents is consistent with the tissue-specific nature of peroxisome proliferator effects.
Mechanism of induction of peroxisome proliferator pleiotropic response
The mechanism by which peroxisome proliferators exert their pleiotropic response has been the subject of much research. Two questions still remain unanswered: (i) how do these structurally diverse agents induce such predictable increases in peroxisome population and selected peroxisomal enzymes in liver cells? and (ii) how is the xenobiotic-induced peroxisome proliferation related to the development of hepatocarcinogenesis?
Despite the structural diversity, the similarity of pleiotropic response strongly favors a common mechanism for coordinate transcriptional regulation of peroxisomal /3-oxidation genes (53, 76) . The possibility that these compounds induce peroxisome proliferation by increasing the influx of lipids into liver (2, 77) , or that these agents serve as substrates for the peroxisomal /3-oxidation system, was once considered, but we have argued against such possibilities as the primary basis for xenobioticinduced peroxisome proliferation (2, 78) . We propose that these agents exert meir effect by a ligand-receptor-mediated mechanism (2,42). The mostly indirect evidence accumulated in favor of this hypothesis includes: (i) tissue-specific predictable biological response (71); (ii) response of extrahepatic hepatocytes to the inductive effects of these compounds (72) (73) (74) (75) ; (iii) inducibility of peroxisome proliferation in hepatocytes in primary cultures maintained in defined medium (79); (iv) induction of specific changes in protein composition, as analyzed by highresolution two-dimensional electrophoresis, in livers of rats treated with peroxisome proliferators whch differ in their chemical structure (80); (v) a rapid and significant increase in the rate of synthesis of mRNAs for peroxisomal /3-oxidation enzymes in liver (53, 76) ; (vi) rapidity of transcriptional response of these genes (53); and (vii) detection of a specific binding moiety in liver cytosol for nafenopin, a clofibrate-like peroxisome proliferator (81) . Preliminary studies in our laboratory have identified a set of proteins in rat liver cytosol which binds to nafenopin affinity column (82) . A dominant 70 kd protein band and three other minor proteins are present when the affinity purified protein(s) was resolved by SDS-polyacrylamide gel electrophoresis. When clofibric acid and ciprofibrate, two compounds which are closely related to nafenopin, were used as affinity ligands, the same 70 kd protein was isolated (83) . Characterization of the nature and molecular properties of peroxisome proliferatorbinding protein(s) is of prime importance in elucidating the mechanism by which these agents exert tissue-specific responses. Further investigation of the receptor-mediated mechanism of action of peroxisome proliferators also requires analysis of the structure-activity relationship of analogs of compounds such as clofibrate and ciprofibrate. Such studies should be of considerable value in correlating the ability of compounds to bind to the receptor and induce peroxisomal /3-oxidation activity. The availability of antibodies as well as cDNA probes to the enzymes of the peroxisomal /3-oxidation system should enable a systematic structure-activity study to evaluate the potencies of the congeners to induce specific mRNAs in liver.
Several studies have now unequivocally established the hepatocarcinogenicity of peroxisome proliferators (2, 32) . It is also clear that these agents are complete carcinogens in that they act both as initiators and promoters (2, (84) (85) (86) . Recently, Glauert et al. (69) demonstrated convincingly that peroxisome proliferators, when fed either alone or after partial hepatectomy, stimulate the appearance of increased numbers of altered hepatocyte foci. In addition, when peroxisome proliferators are fed after the administration of diethylnitrosamine, the number and volume of altered hepatocyte foci and tumors are increased. It is important to point out here that in some short-term in vivo studies no tumor-promoting activity of peroxisome proliferators was discerned (87) (88) (89) . In these studies the only marker employed for quantitating altered hepatocyte foci was GGT. Since this enzyme is not expressed in the preneoplastic and neoplastic lesions of rats fed peroxisome proliferators, use of this marker exclusively may lead to unreliable information. It is also of importance to exercise considerable caution in designing short-term in vivo experiments dealing with initiation and promotion properties of peroxisome proliferators and interpreting negative data because of the unique nature of these compounds and differences in their potencies.
The lack of mutagenicity of all peroxisome proliferators in prokaryotic and eukaryotic test systems (90-93) has generated considerable interest in the mechanism by which these agents induce hepatocellular carcinomas. We have postulated that the carcinogenicity of this novel class of hepatocarcinogens is related to biologically active products of the proliferated peroxisomes rather than to the direct DNA-damaging effect of the chemical (2, 54) . It is well documented that persistent proliferation of peroxisomes and increased synthesis of H 2 O 2 -generating peroxisomal /3-oxidation enzyme system leads to increased oxidative stress in liver (54) . Increases in the induction of peroxisomal /3-oxidation enzymes and the steady-state H 2 O 2 in liver homogenates appear to correlate well with the carcinogenic potential of these xenobiotics (94) (95) (96) (97) (98) . Evidence supporting the role of peroxisome proliferation-mediated oxidative stress as a possible initiation and promotion mechanism in hepatocarcinogenesis has been reviewed previously (2) . This evidence includes: (i) consistent association between the induction of peroxisome proliferation and liver carcinogenesis; (ii) sustained and specific induction of H 2 O 2 -producing /3-oxidation enzymes; (iii) increased intracellular levels of H 2 O 2 in livers of rats with peroxisome proliferation; (iv) increases in hepatic lipofuscin and increased hepatic levels of diene conjugates, indicative of increased lipid peroxidation, in rats chronically treated with peroxisome proliferators; and (v) marked inhibition of peroxisome proliferator-induced hepatocarcinogenesis by antioxidants (60) . The mechanism by which oxidative stress influences initiation and promotion of carcinogenesis, however, remains unknown (99), but it is generally held that H 2 O 2 and other reactive oxygen species (OH, O2" and 'O 2 ) can cause DNA damage either directly or by initiating lipid peroxidation (100-103). Recently Fahl et al. (94) demonstrated that H 2 O 2 generated by peroxisomes isolated from the livers of rats treated with a hypolipidemic agent caused single-strand breaks in supercoiled SV40 DNA molecules under in vitro incubation conditions. However, evidence that peroxisome proliferation and the resultant oxidative stress leads to DNA damage in vivo is lacking (6) . Lack of this evidence does not, however, negate the hypothesis that carcinogenicity by this novel class of agents is due to peroxisome proliferation since: (i) this damge may be so subtle that it is not detectable by the currently available techniques; and (ii) a xenobiotic receptor-mediated mechanism of induction of peroxisome proliferation may result in the amplification of jS-oxidation genes and sustained oxidative stress resulting in these livers may likewise activate or alter oncogenes leading to hepatocarcinogenesis (42, 104) .
Implications for future study
In the past a series of compounds having diverse chemical structures has been identified as hepatic peroxisome proliferators in 634 rodents and certain non-rodent species. These agents share similar biological and biochemical effects and are used as valuable tools to investigate the cellular and molecular events involved in hepatic peroxisome proliferation. Of considerable significance is the observation that these agents also induce hepatocellular carcinomas in rats and mice despite their non-genotoxic nature. The postulated link between xenobiotic receptor-mediated induction of peroxisome proliferation and hepatocarcinogenicity implies that different species may exhibit different degrees of pleiotropic response to these agents. Our knowledge of the mechanism by which peroxisome proliferators and other non-mutagenic carcinogens exert their pleiotropic effect is in a state of infancy. This discussion of the role of peroxisome proliferation in hepatocarcinogenesis will, we hope, stimulate further research in this area of xenobiotic -receptor interactions in the induction of specific pleiotropic response and in understanding the role of oxidative stress in initiation and promotion of liver cancer. We have just begun to identify and characterize the specific recognition molecules or peroxisome proliferator binding proteins (receptors) in cells; these binding proteins may play a major role in the xenobiotic-mediated effects, including neoplastic transformation in liver. These binding proteins may play a major role in cellular adaptation to chronic exposure to chemicals that are incapable of generating electrophilic reactants. The current emphasis on the identification and development of drugs, and other chemicals which are negative in in vitro mutagenic tests using prokaryotes, will most likely lead to the introduction of increasing numbers of non-genotoxic carcinogenic agents for use in the future.
